【摘要】：改革開放以來隨著我國(guó)經(jīng)濟(jì)實(shí)力的不斷增強(qiáng),醫(yī)藥制造業(yè)得到迅猛發(fā)展,在國(guó)民經(jīng)濟(jì)體系中的地位逐步提高,醫(yī)藥制造業(yè)是關(guān)系人民生命健康的重要行業(yè)。隨著人們對(duì)健康意識(shí)的提高,促使醫(yī)藥需求的增加,各國(guó)對(duì)醫(yī)藥領(lǐng)域的發(fā)展也越來越重視,現(xiàn)代醫(yī)藥產(chǎn)業(yè)進(jìn)入快速發(fā)展的階段,同時(shí)也由于其行業(yè)特殊性的存在,醫(yī)藥制造業(yè)也被稱為“永遠(yuǎn)的朝陽產(chǎn)業(yè)”。 目的：通過對(duì)當(dāng)前我國(guó)醫(yī)藥制造業(yè)經(jīng)濟(jì)產(chǎn)出狀況分析了解當(dāng)前醫(yī)藥制造業(yè)經(jīng)濟(jì)發(fā)展?fàn)顩r；構(gòu)建影響因素指標(biāo)體系并對(duì)指標(biāo)體系進(jìn)行量化分析,得出影響我國(guó)醫(yī)藥制造業(yè)經(jīng)濟(jì)產(chǎn)出水平的主要因素及各影響因素在不同時(shí)期的變化狀況。在此基礎(chǔ)上,提出提升我國(guó)醫(yī)藥制造業(yè)經(jīng)濟(jì)產(chǎn)出水平的對(duì)策建議,研究結(jié)果可為醫(yī)藥管理部門和企業(yè)進(jìn)行管理決策提供數(shù)據(jù)支持和參考,同時(shí)也能為相關(guān)領(lǐng)域內(nèi)的研究學(xué)者提供借鑒。 方法：本研究采用定性和定量相結(jié)合方法。采用絕對(duì)數(shù)、構(gòu)成比、同比增長(zhǎng)率等統(tǒng)計(jì)指標(biāo)對(duì)當(dāng)前我國(guó)醫(yī)藥制造業(yè)市場(chǎng)需求狀況及經(jīng)濟(jì)產(chǎn)出狀況進(jìn)行描述性分析；并通過構(gòu)建灰色GM(1,1)預(yù)測(cè)模型對(duì)未來我國(guó)醫(yī)藥制造業(yè)產(chǎn)能狀況進(jìn)行趨勢(shì)預(yù)測(cè)；在文獻(xiàn)分析基礎(chǔ)上,從基本要素投入、醫(yī)藥科技因素、市場(chǎng)需求因素、對(duì)外開放程度因素、產(chǎn)業(yè)發(fā)展環(huán)境因素五大方面共11個(gè)因素,構(gòu)建影響我國(guó)醫(yī)藥制造業(yè)產(chǎn)出的因素指標(biāo)體系。并根據(jù)我國(guó)醫(yī)藥相關(guān)統(tǒng)計(jì)年鑒指標(biāo)數(shù)據(jù)采用灰色關(guān)聯(lián)法對(duì)影響因素進(jìn)行量化處理,從而得出各個(gè)影響因素排序及變化狀況。 結(jié)果：分析結(jié)果顯示,我國(guó)醫(yī)藥制造業(yè)的發(fā)展還存在較多問題,例如醫(yī)藥制造企業(yè)規(guī)模小、集中程度低、地區(qū)醫(yī)藥制造業(yè)發(fā)展不平衡、地區(qū)特色不顯著等,同時(shí)在對(duì)影響因素的分析中發(fā)現(xiàn),我國(guó)醫(yī)藥制造業(yè)產(chǎn)出水平在一定時(shí)期內(nèi)較大程度依賴于資金和勞動(dòng)力的投入,近年來科技因素在工業(yè)發(fā)展過程中的作用有所提升,對(duì)外開放程度因素影響有所減弱,產(chǎn)業(yè)發(fā)展環(huán)境因素和市場(chǎng)需求因素在一定時(shí)期對(duì)醫(yī)藥制造業(yè)經(jīng)濟(jì)產(chǎn)出影響較為穩(wěn)定。 結(jié)論：本研究以國(guó)家統(tǒng)計(jì)局、國(guó)家衛(wèi)生和計(jì)劃生育委員會(huì)、國(guó)家工業(yè)與信息化部、中國(guó)醫(yī)藥保健品進(jìn)出口商會(huì)等國(guó)家醫(yī)藥管理與研究部門的權(quán)威數(shù)據(jù)為基礎(chǔ),分析數(shù)據(jù)真實(shí)可靠。在分析過程中以2006年和2010年我國(guó)28個(gè)省的影響因素?cái)?shù)據(jù)為樣本,結(jié)合數(shù)據(jù)樣本量及數(shù)據(jù)的分布特征,選取灰色關(guān)聯(lián)分析方法分析較為合適。在綜合分析基礎(chǔ)上進(jìn)一步探討改進(jìn)建議與對(duì)策,從而提升我國(guó)醫(yī)藥制造業(yè)經(jīng)濟(jì)產(chǎn)出水平,促進(jìn)醫(yī)藥制造業(yè)發(fā)展。
[Abstract]:Since the reform and opening to the outside world, the pharmaceutical manufacturing industry has been developing rapidly with the increasing economic strength of our country, and its position in the national economic system has been gradually improved. The pharmaceutical manufacturing industry is an important industry related to the life and health of the people. With the improvement of people's awareness of health and the increasing demand for medicine, more and more attention has been paid to the development of the field of medicine. The modern medicine industry has entered the stage of rapid development, and at the same time, because of the existence of its particularity, Pharmaceutical manufacturing is also known as the "sunrise industry forever." Objective: to analyze the economic output of pharmaceutical manufacturing industry in China. The index system of the influencing factors is constructed and the quantitative analysis of the index system is carried out. The main factors affecting the economic output level of the pharmaceutical manufacturing industry in China and the changes of the influencing factors in different periods are obtained. On this basis, the countermeasures and suggestions to improve the economic output level of pharmaceutical manufacturing industry in China are put forward. The research results can provide data support and reference for pharmaceutical management departments and enterprises to make management decisions. At the same time, it can also provide reference for researchers in related fields. Methods: qualitative and quantitative methods were used in this study. The market demand and economic output of pharmaceutical manufacturing industry in China are analyzed in terms of absolute number, composition ratio, annual growth rate and so on. And through the construction of grey GM (1 ~ 1) forecasting model, the trend of the future pharmaceutical manufacturing capacity in China is forecasted. On the basis of literature analysis, there are 11 factors in five aspects: input of basic elements, factors of pharmaceutical science and technology, factors of market demand, factors of degree of opening to the outside world, and environmental factors of industrial development. To construct the index system of factors influencing the output of pharmaceutical manufacturing industry in China. According to the index data of the medical statistics yearbook of our country, grey correlation method is used to quantify the influencing factors, and the order and change of the influencing factors are obtained. Results: the results show that there are still many problems in the development of pharmaceutical manufacturing industry in China, such as the small scale of pharmaceutical manufacturing enterprises, low concentration, unbalanced development of regional pharmaceutical manufacturing industry, unremarkable regional characteristics, etc. At the same time, through the analysis of the influencing factors, it is found that the output level of pharmaceutical manufacturing industry in China depends on the investment of capital and labor to a large extent in a certain period of time, and in recent years, the role of scientific and technological factors in the process of industrial development has been improved. The influence of the degree of opening to the outside world is weakened, and the factors of industrial development environment and market demand have a stable effect on the economic output of pharmaceutical manufacturing industry in a certain period of time. Conclusion: this study is based on the authoritative data of the National Bureau of Statistics, the National Health and Family Planning Commission, the Ministry of Industry and Information Technology, and the China Chamber of Commerce for the Import and Export of Health products. The analytical data are true and reliable. In the process of analysis, taking the data of the influencing factors of 28 provinces in 2006 and 2010 as samples, combining the sample size and the distribution characteristics of the data, it is more appropriate to select the grey relational analysis method to analyze. On the basis of comprehensive analysis, suggestions and countermeasures for improvement are further discussed in order to improve the economic output level of Chinese pharmaceutical manufacturing industry and promote the development of pharmaceutical manufacturing industry.
【學(xué)位授予單位】：北京中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：F426.72

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 陸靜超;經(jīng)濟(jì)增長(zhǎng)理論的沿革與創(chuàng)新——評(píng)新古典增長(zhǎng)理論與新增長(zhǎng)理論[J];哈爾濱工業(yè)大學(xué)學(xué)報(bào)(社會(huì)科學(xué)版);2004年05期

2 張世龍;劉琳琳;任佳希;;我國(guó)區(qū)域醫(yī)藥制造業(yè)競(jìng)爭(zhēng)力評(píng)價(jià)與分析——基于大陸省經(jīng)濟(jì)區(qū)域數(shù)據(jù)的實(shí)證研究[J];杭州電子科技大學(xué)學(xué)報(bào)(社會(huì)科學(xué)版);2011年01期

3 解曉燕;繆建營(yíng);;國(guó)際原油價(jià)格主控因素的實(shí)證研究——基于2006-2011年的時(shí)間序列數(shù)據(jù)分析[J];價(jià)格理論與實(shí)踐;2011年12期

4 岳純;趙洪進(jìn);;FDI和產(chǎn)業(yè)規(guī)模與我國(guó)醫(yī)藥產(chǎn)業(yè)市場(chǎng)集中度關(guān)系的研究[J];商業(yè)經(jīng)濟(jì);2009年24期

5 熊廣勤;;FDI、進(jìn)出口貿(mào)易與產(chǎn)業(yè)集群對(duì)中部地區(qū)經(jīng)濟(jì)增長(zhǎng)影響的實(shí)證研究[J];商業(yè)經(jīng)濟(jì);2010年23期

6 海聞;國(guó)際貿(mào)易理論的新發(fā)展[J];經(jīng)濟(jì)研究;1995年07期

7 王新,朱文新;中國(guó)醫(yī)藥工業(yè)影響因素的組合作用分析[J];吉林工業(yè)大學(xué)自然科學(xué)學(xué)報(bào);1999年01期

8 梁萊歆;張煥鳳;袁藝;;基于DEA的企業(yè)R&D有效性研究[J];科研管理;2006年06期

9 江靜;;中國(guó)省際R&D強(qiáng)度差異的決定與比較——基于1998-2004年的實(shí)證分析[J];南京大學(xué)學(xué)報(bào)(哲學(xué).人文科學(xué).社會(huì)科學(xué)版);2006年03期

10 鄧力群;;我國(guó)R&D投入對(duì)TFP貢獻(xiàn)的實(shí)證分析[J];南京社會(huì)科學(xué);2011年04期

，

本文編號(hào)：2356761